E-Learning

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) released interim data from a Phase 1 trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis. The trial will enroll 64 patients with moderate to severe atopic dermatitis who previously failed one prior topical or systemic therapy. These doses were selected based on the company’s prior experience evaluating soquelitinib in T-cell lymphoma patients. The company is reporting complete results from Cohort 1 of the trial, which inc

Tender rejection rate rises as holidays approach The tender rejection rate has risen steadily since early October despite tender volume declining. That implies that capacity is leaving the market, which […] The post Freight market shows additional signs of recovery appeared first on FreightWaves.

(Bloomberg) -- While concern has grown in the past week that narrowing market breadth has tapped the brakes on the S&P 500 Index’s blistering rally, it turns out that stock bulls are still stepping in to snap up shares ahead of the Federal Reserve’s interest-rate decision.Most Read from BloombergHow California Sees the World, and ItselfThe index’s DVAN trend line — a proprietary divergence analysis that measures buying or selling pressure — has been on a buying streak since Election Day, with in

Next year's top pick for hedge fund strategies is so-called macro, with U.S. President-elect Donald Trump centre-stage as investors bet on how global policy decisions will impact economic conditions and play out in financial markets. Hedge fund returns benefited this year from wild market swings sparked by politics such as November's U.S. election, and twists in monetary policy such as Bank of Japan rate hikes. And investors are readying for more volatility in the year ahead, seven hedge fund investors and portfolio managers told Reuters and a recent survey showed.

On Wednesday, Merck & Co Inc (NYSE:MRK) and Hansoh Pharma, a Chinese biopharmaceutical company, entered into an exclusive global license agreement for HS-10535, an investigational preclinical oral small molecule GLP-1 receptor agonist. Under the agreement, Hansoh Pharma has granted Merck an exclusive global license to develop, manufacture, and commercialize HS-10535. Hansoh Pharma will receive an upfront payment of $112 million and is eligible to receive up to $1.9 billion in milestone payments

(Bloomberg) -- A whopping 1130% rally in the shares of a Brazilian waste management company is drawing the attention of the country’s stock exchange operator. Most Read from BloombergNYPD Car Chases Are Becoming More Frequent — and More DangerousB3 SA, the company behind Brazil’s stock exchange, requested clarification on “atypical fluctuations” in the shares of Ambipar Participacoes e Empreendimentos SA that took place between Dec. 11 and 13, according to a note. On those days, the stock surged

A new report identifies data content management as the primary driver of growth in the pharmaceuticals market.

(Bloomberg) -- First it was a collapse in the currency. Now the rest of Brazil’s financial markets are in the cross-hairs as investors lose faith in the government’s ability to contain a deepening fiscal crisis.Most Read from BloombergHow California Sees the World, and ItselfThe selloff that sent the real plunging to a record low is engulfing everything from stocks to local-currency debt to dollar bonds, with traders even piling into hedges against a sovereign default. Market watchers say extrao

A group of current and former OpenAI employees are eligible to cash out up to $10 million worth of shares as part of the company’s $1.6 billion tender offer to SoftBank, a source has told Fortune.

U.S. equities gained at midday ahead of what's expected to be the announcement of another interest-rate cut from the Federal Reserve.